Rugen Therapeutics (Suzhou), a biomed R&D company at BioBay in Suzhou Industrial Park, is working on small molecule drugs to treat obsessive-compulsive disorder, Alzheimer, acute brain and spinal cord injury, and autism by affecting central nervous system directly.
Rugens founders include Guoping Feng, PhD, Poitras Chair Professor - MIT and a member of the Broad Institute of MIT and Harvard University and Zhigang He, PhD, Professor, Childrens Hospital Boston and Harvard Medical School.
Rugen Therapeutics (Suzhou), a biomed R&D company at BioBay in Suzhou Industrial Park, is working on small molecule drugs to treat obsessive-compulsive disorder, Alzheimer, acute brain and spinal cord injury, and autism by affecting central nervous system directly.
Rugens founders include Guoping Feng, PhD, Poitras Chair Professor – MIT and a member of the Broad Institute of MIT and Harvard University and Zhigang He, PhD, Professor, Childrens Hospital Boston and Harvard Medical School.[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]
In Nov 2015, Allergan (NYSE: AGN) and Rugen, collaborate to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). Under the terms, Rugen received an upfront initiation fee, and is entitled to development stage initiation and success-based milestone payments for advancing compounds. Allergan will have the exclusive option to acquire all rights, following clinical proof of concept studies.
Rugen Therapeutics is funded by the F-Prime Biomedical Research Initiative (FBRI), Fidelity Bioscience.
Recover your password.
A password will be e-mailed to you.